StockNews.AISignal intelligence
Biomotion Sciences Ordinary Shares · NASDAQ · Healthcare
Browse public SLXN signals with their source context and measured market impact. Open any signal for its permanent analysis page.
SLXN stock surged 14.83% to $5.15, high trading volume observed. New preclinical data show SIL204 effectively targets pancreatic cancer. Statistically significant tumor burden reductions noted in major metastatic sites. Phase 2/3 trials scheduled for early 2026 with regulatory submissions approaching. Public offering of shares and warrants priced at $4.
View signal analysisSilexion's SIL204 shows effectiveness in pancreatic cancer models. Marked reduction in tumor growth across various KRAS mutations. SIL204 indicates strong potential for treatment via subcutaneous administration. Dramatic 25.23% stock uptick post-announcement to $1.39.
View signal analysisSilexion's SIL-204 shows significant synergy with key pancreatic cancer drugs. Preclinical tests indicate improved efficacy of SIL-204 with chemotherapy agents. A public offering of 3.7 million shares raises $5 million for Silexion. Silexion aims to progress SIL-204 to clinical trials by mid-2026. SLXN shares recently experienced a 42.96% decline.
View signal analysisSilexion's SLXN stock rose 21.72% after Phase 2 trial results. LODER demonstrated a 56% objective response rate in patients. Patients with resectable tumors saw ORR increase to 67%. Overall survival improved by 9.3 months with LODER and chemotherapy. Silexion is developing SIL-204, targeting broader KRAS mutations.
View signal analysis